Zoetis (NYSE:ZTS) Stock Rating Upgraded by Zacks Research

Zoetis (NYSE:ZTS) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday, Zacks reports.

Other equities analysts also recently issued research reports about the stock. Morgan Stanley set a $85.00 price objective on shares of Zoetis in a research report on Friday, August 7th. BNP Paribas Exane lowered their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. JPMorgan Chase & Co. dropped their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. UBS Group increased their price target on shares of Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, HSBC reduced their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Seven analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $98.40.

Zoetis Trading Down 3.4%

Shares of ZTS stock opened at $78.25 on Monday. The business’s 50 day moving average is $74.84 and its two-hundred day moving average is $94.35. Zoetis has a twelve month low of $68.77 and a twelve month high of $147.46.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the company earned $1.76 EPS. Zoetis’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts predict that Zoetis will post 6.15 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Management Co. acquired a new stake in Zoetis during the 2nd quarter valued at $25,000. Dunhill Financial LLC boosted its position in shares of Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares during the period. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis in the first quarter worth $28,000. Root Financial Partners LLC grew its holdings in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. Finally, Wellington Grp LLC grew its holdings in shares of Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after buying an additional 267 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.